Recent advances in cancer treatment have emerged from new immunotherapies targeting T-
cell inhibitory receptors, including cytotoxic T-lymphocyte associated antigen (CTLA)-4 and …

Effective clinical cancer immunotherapies, such as administration of the cytokine IL-2,
adoptive cell transfer (ACT) and the recent success of blockade of the checkpoint …

Limited evidence exists that humans mount a mutation-specific T cell response to epithelial
cancers. We used a whole-exomic-sequencing-based approach to demonstrate that tumor …

Multiple genetic events and subsequent clonal evolution drive carcinogenesis, making
disease elimination with single-targeted drugs difficult. The multiplicity of gene mutations …

Harnessing the immune system to eradicate malignant cells is becoming a most powerful
new approach to cancer therapy. FDA approval of the immunotherapy-based drugs …

Neoantigens are antigens encoded by tumor-specific mutated genes. Studies in the past few
years have suggested a key role for neoantigens in cancer immunotherapy. Here we review …

The importance of the immune system in conferring protection against pathogens like
viruses, bacteria, and parasitic worms is well established. In contrast, there is a long-lasting …

Adoptive T cell therapy has achieved dramatic success in a clinic, and the Food and Drug
Administration approved two chimeric antigen receptor-engineered T cell (CAR-T) therapies …

The technological advances occurred in the last few years have led to a great increase in
the number of tumor associated antigens (TAA) that are currently available for clinical …

Cancer genome sequencing has enabled the rapid identification of the complete repertoire
of coding sequence mutations within a patient's tumor and facilitated their use as …